SLAM family member 7 is a protein that in humans is encoded by the SLAMF7gene.[5][6][7]
The surface antigen CD319 (SLAMF7) is a robust marker of normal plasma cells and malignant plasma cells in multiple myeloma. In contrast to CD138 (the traditional plasma cell marker), CD319/SLAMF7 is much more stable and allows robust isolation of malignant plasma cells from delayed or even cryopreserved samples.[8]
Elotuzumab is an antibody that targets this protein.
^Boles KS, Mathew PA (Feb 2001). "Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily". Immunogenetics. 52 (3–4): 302–7. doi:10.1007/s002510000274. PMID11220635.
^Frigyesi I, Adolfsson J, Ali M, Christophersen MK, Johnsson E, Turesson I, Gullberg U, Hansson M, Nilsson B (Feb 2014). "Robust isolation of malignant plasma cells in multiple myeloma". Blood. 123 (9): 1336–40. doi:10.1182/blood-2013-09-529800. PMID24385542.
Further reading
Claus M, Meinke S, Bhat R, Watzl C (2007). "Regulation of NK cell activity by 2B4, NTB-A and CRACC". Frontiers in Bioscience. 13 (13): 956–65. doi:10.2741/2735. PMID17981603.
Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M (Nov 2001). "Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family". Journal of Immunology. 167 (10): 5517–21. doi:10.4049/jimmunol.167.10.5517. PMID11698418.
Tovar V, del Valle J, Zapater N, Martin M, Romero X, Pizcueta P, Bosch J, Terhorst C, Engel P (Sep 2002). "Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors". Immunogenetics. 54 (6): 394–402. doi:10.1007/s00251-002-0483-3. PMID12242590.
Del Valle JM, Engel P, Martín M (May 2003). "The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2)". The Journal of Biological Chemistry. 278 (19): 17430–7. doi:10.1074/jbc.M301569200. PMID12621057.{{cite journal}}: CS1 maint: unflagged free DOI (link)
Lee JK, Boles KS, Mathew PA (Oct 2004). "Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs". European Journal of Immunology. 34 (10): 2791–9. doi:10.1002/eji.200424917. PMID15368295.
Lee JK, Mathew SO, Vaidya SV, Kumaresan PR, Mathew PA (Oct 2007). "CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes". Journal of Immunology. 179 (7): 4672–8. doi:10.4049/jimmunol.179.7.4672. PMID17878365.
Malaer JD, Mathew PA (Aug 2017). "CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma". American Journal of Cancer Research. 7 (8): 1637–41. PMID28861320.